The SEC classifies these issuers under “Biological Products, (No Diagnostic Substances)” (SIC 2836). A shared code is a starting point for finding comparable businesses. Product mix, geography and customers can still differ substantially. Read the company descriptions before treating the group as direct competitors.
Align the reporting periods before comparing annual results. Companies with different year ends report different 12-month windows.
| Fiscal year end (SEC) | Companies |
|---|---|
| December 31 | AMGN, BIIB, GILD, MRNA |
| June 30 | TECH |
Amgen is one of the largest biotechnology companies, with therapies spanning cardiovascular disease, oncology, and inflammation. It is also advancing candidates in the fast-growing obesity-treatment market.
Bio-Techne makes reagents, proteins, and instruments used in biological research and diagnostics.
Biogen develops treatments for neurological diseases such as multiple sclerosis and Alzheimer's.
Gilead is a biopharmaceutical company with leadership in HIV and viral-disease treatments. It has expanded into oncology through acquisitions and its cell-therapy platform.
Moderna develops messenger-RNA vaccines and therapeutics, including its COVID-19 vaccine.
Compare Amgen Inc. and Biogen Inc.: business context, fiscal calendars and official filings.
Compare Amgen Inc. and Gilead Sciences, Inc.: business context, fiscal calendars and official filings.
Compare Amgen Inc. and Moderna, Inc.: business context, fiscal calendars and official filings.
Compare Amgen Inc. and Bio-Techne Corporation: business context, fiscal calendars and official filings.
Compare Biogen Inc. and Gilead Sciences, Inc.: business context, fiscal calendars and official filings.
Compare Biogen Inc. and Moderna, Inc.: business context, fiscal calendars and official filings.
Compare Biogen Inc. and Bio-Techne Corporation: business context, fiscal calendars and official filings.
Compare Gilead Sciences, Inc. and Moderna, Inc.: business context, fiscal calendars and official filings.
Industry codes and annual filing references come from the SEC submissions snapshot linked to each issuer in our company catalog (snapshot ; newer filings may exist). Only groups with at least three distinct issuers, business descriptions and annual filing links are included. Multiple share classes of one issuer count as one company. This is a coverage directory, not a complete industry census or a ranking of investments.
SEC Standard Industrial Classification code list explains the classification system. Read our research methodology or browse all industry directories.
Financials describe the business. The next question is which assumptions an investment thesis depends on. Explore the member reports below for analysis of catalysts, risks, and what would change the view. $39/month or $249/year.
Members-only research
$39/mo or $249/yr · cancel future renewals anytime · sources included